Table 2(a).

The prescription dose, mean dose $({\mathrm{D}}_{\text{mean}})$, the dose received by 95% of the volume $({\mathrm{D}}_{95})$, and maximum dose $({\mathrm{D}}_{\text{max}})$ to the PTVs for the XiO, Prowess, and KonRad plans.

Maximum Dose (Gy)			$D_{\mathit{95}}$ (Gy)			Mean Dose (Gy)
KonRad	Prowess	XiO	KonRad	Prowess	XiO	KonRad	Prowess	XiO	Prescribed dose (Gy)	Tumor Site
61	58.8	62	51.2	51.3	51.1	53.9	53	52.5	54	Low‐grade Glioma
69.6	71	69	61.6	61.5	62	64.4	66	63.9	64.8	Parotid Carcinoma
53.6	53.9	54	47.8	47.5	47.7	50	51.5	50	50	Pituitary Adenoma
51.62	51.7	52	42.8	42.7	43.1	44.75	46	45	45	Retinoblastoma
73.3	70.7	71.4	61.6	61.5	62	65.1	66.6	65.3	64.8	Parotid Carcinoma
22.3	21.6	22.3	19	18.8	19.1	19.7	20.2	19.8	19.8	High‐risk Medulloblastoma
36.2	35.9	36.4	30.7	30.8	30.9	32.5	33.3	32.3	32.4	Low‐risk Medulloblastoma
41.4	42	41.5	34.4	34.2	34	36.3	38	36.6	36	Nasolaboil RMS
60	62	57.6	47.8	47.8	47.9	50.6	51.8	51	50.4	Rhabdomyosarcoma (RMS)
68.8	65.8	63	56.43	56.4	56.2	59.9	61	59	59.4	Ependymoma
73.5	68.7	69.8	57	57	57.1	59.9	61.6	60	60	Maxillary Sarcoma